Beta-blockers for congestive heart failure: what is the current consensus?

Related Experiment Videos

R T Tsuyuki1, F A McAlister, K K Teo

  • 1Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.

Drugs & Aging
|March 25, 2000
PubMed

Insights

Beta-blockers show significant survival benefits for patients with congestive heart failure (CHF), reducing mortality and hospitalizations. Evidence supports their use across diverse CHF populations, including the elderly, though careful initiation is advised.

Area of Science:

  • Cardiology
  • Pharmacology
  • Heart Failure Management

Background:

  • Congestive heart failure (CHF) remains a significant health concern with high mortality despite existing treatments like ACE inhibitors.
  • Neurohormonal systems, including the sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS), are implicated in CHF progression.
  • Long-term activation of the SNS can negatively impact cardiac function and patient outcomes.

Purpose of the Study:

  • To review the existing literature on the efficacy of beta-blockers in managing patients with congestive heart failure (CHF).
  • To evaluate the impact of beta-blocker therapy on mortality, morbidity, and other clinical outcomes in CHF patients.

Main Methods:

  • Systematic review and meta-analysis of published randomized clinical trials (RCTs) involving beta-blockers in CHF patients.
  • Analysis of data from large-scale clinical trials, including those terminated early due to demonstrated survival benefits.

Main Results:

  • Randomized clinical trials and systematic overviews consistently demonstrate that beta-blockers significantly reduce mortality and hospitalizations in CHF patients.
  • Beta-blockers show benefits in improving ejection fraction and reducing the need for transplantation.
  • Effects on exercise tolerance, New York Heart Association Function Class (NYHA-FC), and quality of life remain less definitive.

Conclusions:

  • Beta-blocker therapy is recommended for a broad range of CHF patients, including the elderly, due to proven survival benefits.
  • Careful initiation and titration of beta-blockers are necessary to manage potential transient worsening of CHF symptoms.
  • Further research is needed to determine if all beta-blockers offer equal efficacy in CHF management.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...